A beneficial effect of treatment with reconstituted High Density Lipoprotein (rHDL), containing plasma derived apolipoprotein A-I (apoA-I) and phosphatidylcholine (PC), was described in models for atherosclerosis, myocardial infarction, stroke and endotoxemia, and in clinical trials demonstrating effects on atherosclerotic plaques [1], [2]. The gene discussed is APOA1; the disease is myocardial infarction.